Case guide

Black Women and Hair Relaxer Claim Questions

The study raises concerns for Black women because use patterns differ. It did not find a different research link by race.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202612 sources

This may apply to you if

  • List the chemical relaxer or straightener brands you used and your best use dates.
  • Have the report that names your cancer and the diagnosis date ready to discuss.
  • Ask a lawyer to check the product history, claim rules and filing time. The study’s use categories are not a claim cutoff.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

Mary M. Rowland · U.S. District Court, Northern District of Illinois · United States District Judge

Finding: The September 24, 2026 court notice schedules the first federal test trial for September 7, 2027. A scheduled test trial is not a payment date or a ruling that every claim succeeds.

Notification of docket entry, Document 2041 (opens in a new tab) · Sep 24, 2026 · Checked Oct 3, 2026

Che-Jung Chang · National Institute of Environmental Health Sciences, Epidemiology Branch · First-listed study author

Finding: The Sister Study analysis found an association between reported straightening-product use and later uterine cancer. The authors call for more research; the finding does not prove a product caused one person’s cancer.

Use of Straighteners and Other Hair Products and Incident Uterine Cancer (opens in a new tab) · Dec 8, 2022 · Checked Oct 3, 2026

The evidence and its limits

National Institute of Environmental Health Sciences · Journal of the National Cancer Institute · 2022

Sister Study analysis of hair products and uterine cancer

Design:
Cohort
Participants:
33,947 women aged 35–74 with a uterus at enrollment
Finding:
Reported straightening-product use was associated with later uterine cancer; the association was stronger in the study’s frequent-use group.
Main limitation
Observational data and self-reported use in the prior year; the authors call for replication and identifying the chemicals involved. It does not prove that a particular product caused one person’s illness.

Read the source: Sister Study analysis of hair products and uterine cancer (opens in a new tab) · Checked Oct 3, 2026

The short answer

Why did NIEHS discuss Black women in the study?
About 60% of study users identified as Black women. That describes the people who reported use. It is not a share of all Black women or all claimants. [12]
Did the study find a different link by race?
It did not find a difference by race in the link between use and womb cancer. That is not proof that risk is identical for every person. [12]
Does being Black decide whether I have a claim?
No group label can decide your case on this page. Ask a lawyer to check your product, health records, dates and applicable law. [2]
Can the study tell me which product caused my illness?
No. It did not collect brands or ingredients. It cannot identify your past package or prove the cause of your own diagnosis. [12]

What rules a case out

Not covered by this case

  • Race does not establish the cause of one person’s cancer.
  • A group finding does not decide who qualifies for a claim.
  • The study did not identify brands or chemicals used by each person.

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

The study raises concerns for Black women because use patterns differ. It did not find a different research link by race. Your product, diagnosis and claim need their own review.

Why did NIEHS discuss Black women in the study?

About 60% of study users identified as Black women. That describes the people who reported use. It is not a share of all Black women or all claimants.

The October 2022 release says use may start earlier and be more common among Black women. It says those patterns can make the findings especially relevant. The study’s reported users are a research subgroup, not a population estimate or an automatic legal class.

Does being Black decide whether I have a claim?

No group label can decide your case on this page. Ask a lawyer to check your product, health records, dates and applicable law.

The transfer order describes allegations of reproductive harm and coordinates federal cases. It does not give this guide a race-based acceptance rule. A diagnosis and study finding still need individual evidence and legal assessment.

The study’s frequent-use group is not a universal legal cutoff. Give the use history you know and mark gaps. Do not change your account to fit a number from an ad.

Can the study tell me which product caused my illness?

No. It did not collect brands or ingredients. It cannot identify your past package or prove the cause of your own diagnosis.

The original cohort compared reported product use with later uterine cancer. It was not a trial assigning people to use products. A group association cannot by itself choose a treatment, identify a company at fault or value your case.

How can I prepare without a complete product history?

List what you remember and what existing records show. Mark approximate dates and unknown brands clearly. Keep those details separate from the health diagnosis.

Ask providers how to request diagnosis and care reports they maintain. Federal access rules have exceptions and do not promise every old record exists. A current product label cannot fill gaps in past use or care records.

Scientific evidence for this case

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Ask a law firm to review your case

Questions about this guide

Is the CROWN Act related to the hair relaxer lawsuit?

The CROWN Act (Creating a Respectful and Open World for Natural Hair) prohibits employment and educational discrimination based on hair texture. While not directly a chemical safety law, CROWN Act proponents argue that hair discrimination created the coercive pressure that drove Black women to use chemical relaxers — making the discrimination itself a contributing cause of the chemical exposure. Over 24 states have enacted CROWN Act legislation.

Why were products marketed to children ("Just for Me")?

"Just for Me" (made by Godrej/Namaste) was explicitly marketed to and used on Black girls, introducing EDC exposure during critical childhood developmental windows. Early-life exposure to estrogen-mimicking chemicals can alter reproductive development and increase lifetime cancer susceptibility. The marketing of chemical relaxers to children is particularly damaging to the defendants' position in the litigation.

I'm a Black woman who never used relaxers but got uterine cancer. Is this related?

While the lawsuit specifically targets chemical hair relaxer exposure, uterine cancer has many risk factors beyond relaxer use. If you never used chemical hair relaxers, the connection may not apply to your situation. However, other hair products (Brazilian blowouts, keratin treatments) containing formaldehyde may also be relevant. Consult an attorney if you used any chemical hair straightening products.

Sources

  1. Court docket notice 2041, September 24, 2026 (primary court-document mirror)Court docket notice 2041, September 24, 2026 (primary court-document mirror) · court
  2. JPML transfer order, February 6, 2023JPML transfer order, February 6, 2023 · court
  3. Chang et al.: original study abstract, 2022Chang et al.: original study abstract, 2022 · study
  4. JPML pending actions report, October 1, 2026 (cached primary PDF)JPML pending actions report, October 1, 2026 (cached primary PDF) · court
  5. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  6. Court guide: filing time limitsCourt guide: filing time limits · court
  7. Health-record access, 45 CFR 164.524Health-record access, 45 CFR 164.524 · regulator
  8. JNCI 2022 original author abstract via PubMedNational Library of Medicine · study
  9. Hair Relaxer Use and Risk of Uterine Cancer in the Black Women's Health StudyEnvironmental Research · 2023 · study
  10. Use of Hair Products in Relation to Ovarian Cancer RiskCarcinogenesis · 2021 · study
  11. Scheduling posture in MDL-3060 (N.D. Ill., Judge Mary Rowland): the court took direct control of bellwether selection (April 2026), scrapping the party alternating-picks system; bellwether fact discovery closed June 10, 2026; case-specific Daubert and summary judgment motions due Nov 16, 2026; first trials broadly expected 2027. 11,877 cases pending as of July 1, 2026 (fourth-largest MDL). No verdicts or settlements yet. CAVEAT: documented only via litigation-tracker blogs (llamalab.ai, mdlupdate.com) — last-resort sources, no court record or major-press confirmation fetched.llamalab.ai · Jul 1, 2026 · court
  12. NIEHS: 2022 hair-straightener uterine study release

Checked against 11 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026